The challenges associated with molecular targeted therapies for glioblastoma
Autor: | Toni Rose Jue, Kerrie L. McDonald |
---|---|
Rok vydání: | 2015 |
Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Malignant brain tumor Molecular Targeted Therapies Antineoplastic Agents urologic and male genital diseases 03 medical and health sciences Therapeutic approach 0302 clinical medicine Internal medicine medicine Humans Molecular Targeted Therapy Chemotherapy Temozolomide urogenital system business.industry Brain Neoplasms medicine.disease female genital diseases and pregnancy complications nervous system diseases Neoplasm Proteins 030104 developmental biology Neurology 030220 oncology & carcinogenesis Immunology Mutation Biomarker (medicine) Neurology (clinical) Personalized medicine business Glioblastoma medicine.drug |
Zdroj: | Journal of neuro-oncology. 127(3) |
ISSN: | 1573-7373 |
Popis: | Glioblastoma (GBM) is the most aggressive malignant brain tumor in adults. Improvements in the treatment of GBM have remained static since the advent of the standard therapy which includes radiation with concurrent and adjuvant temozolomide treatment. Developing treatment and diagnostic or companion biomarker combinations is transforming the way we treat numerous cancers. However, can this emerging paradigm be also effective for GBM? Can GBM be treated the same way as other cancers? Here we review the challenges for a personalized molecular targeted therapeutic approach in GBM. The specific challenges for establishing a personalized molecular targeted medicine program for GBM patients include overcoming the blood brain barrier, unravelling the intra- and inter-heterogeneity that exists and the importance of developing more relevant animal models that recapitulate a patient's GBM tumor. |
Databáze: | OpenAIRE |
Externí odkaz: |